Prices are updated after-hours
Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
symbols : BYSI    save search
BeyondSpring Announces First Patient Dosed with Pembrolizumab, Plinabulin Plus Etoposide/Platinum in a Phase 2 Investigator-initiated Study of First-Line Extensive-Stage Small-Cell Lung Cancer
Published: 2024-03-25 (Crawled : 11:00) - globenewswire.com
BYSI | $1.805 2.56% 26K twitter stocktwits trandingview |
Health Technology
 | | O: 0.0% H: 12.18% C: 11.22%
first lung cancer study
BeyondSpring Regains Compliance with Nasdaq Minimum Bid Price and Periodic Filing Requirements
Published: 2024-02-26 (Crawled : 13:00) - globenewswire.com
BYSI | $1.805 2.56% 26K twitter stocktwits trandingview |
Health Technology
 | | O: -1.83% H: 12.15% C: 11.21%
nasdaq
BeyondSpring Receives Nasdaq Delinquency Notice Regarding Late Filing of Its Form 6-K
Published: 2024-01-10 (Crawled : 20:00) - beyondspringpharma.com
BYSI | $1.805 2.56% 26K twitter stocktwits trandingview |
Health Technology
 | | O: 1.1% H: 2.18% C: -6.57%
nasdaq
BeyondSpring Receives Nasdaq Notice Regarding Minimum Bid Price Requirements
Published: 2023-12-18 (Crawled : 22:00) - globenewswire.com
BYSI | $1.805 2.56% 26K twitter stocktwits trandingview |
Health Technology
 | | O: -6.93% H: 9.57% C: 1.06%
nasdaq
BeyondSpring Presents Poster Highlighting Preclinical and Clinical POC Immunomodulating Activity of Plinabulin Inducing Dendritic Cell Maturation and Re-sensitization in Immunotherapy Refractory Tumors when Combined with Radiation and PD-1/PD-L1 Inhibitors
Published: 2023-11-07 (Crawled : 12:00) - beyondspringpharma.com
BYSI | $1.805 2.56% 26K twitter stocktwits trandingview |
Health Technology
 | | O: -5.43% H: 7.6% C: 4.03%
plinabulin tumors cell preclinical immunotherapy poc
BeyondSpring and Professor K. Eisenmann of the University of Toledo College of Medicine Present Poster Highlighting Plinabulin’s Anti-cancer Efficacy in Primary and Recurrent Glioblastoma Patient Derived Invasive Neurosphere Models
Published: 2023-10-31 (Crawled : 12:00) - globenewswire.com
LLY | $749.215 -0.21% 1.4M twitter stocktwits trandingview |
Health Technology
 | | O: -0.03% H: 0.0% C: 0.0%
BYSI | $1.805 2.56% 26K twitter stocktwits trandingview |
Health Technology
 | | O: -6.73% H: 12.37% C: 2.06%
glioblastoma
BeyondSpring Regains Compliance with Nasdaq Minimum Bid Price Requirement
Published: 2023-10-30 (Crawled : 12:00) - globenewswire.com
BYSI | $1.805 2.56% 26K twitter stocktwits trandingview |
Health Technology
 | | O: 0.94% H: 0.47% C: -2.8%
nasdaq
SEED Therapeutics Discloses Novel Molecular Glue IND Candidate for Cancer at “Targeted Protein Degradation Think Tank” Symposium
Published: 2023-10-26 (Crawled : 13:00) - globenewswire.com
LLY | $749.215 -0.21% 1.4M twitter stocktwits trandingview |
Health Technology
 | | O: -1.68% H: 0.0% C: 0.0%
BYSI | $1.805 2.56% 26K twitter stocktwits trandingview |
Health Technology
 | | O: 0.0% H: 7.14% C: -5.36%
candidate symposium cancer protein therapeutics molecular
SEED Therapeutics, a BeyondSpring Subsidiary, Appoints Mr. Ko-Yung Tung to the Board of Directors
Published: 2023-10-23 (Crawled : 12:00) - globenewswire.com
BYSI | $1.805 2.56% 26K twitter stocktwits trandingview |
Health Technology
 | | O: 2.0% H: 7.84% C: 1.96%
BeyondSpring Receives Nasdaq Notice Regarding Minimum Bid Price Requirements
Published: 2023-10-04 (Crawled : 20:00) - globenewswire.com
BYSI | $1.805 2.56% 26K twitter stocktwits trandingview |
Health Technology
 | | O: -4.89% H: 9.61% C: 7.89%
nasdaq
BeyondSpring and Leading Cancer Center to Present Poster at SITC’s 38th Annual Meeting
Published: 2023-09-27 (Crawled : 14:00) - globenewswire.com
BYSI | $1.805 2.56% 26K twitter stocktwits trandingview |
Health Technology
 | | O: -2.96% H: 9.33% C: 0.0%
cancer meeting
BeyondSpring to Participate in the R.W. Baird’s 2023 Global Healthcare Conference
Published: 2023-09-07 (Crawled : 12:00) - globenewswire.com
BYSI | $1.805 2.56% 26K twitter stocktwits trandingview |
Health Technology
 | | O: -2.13% H: 3.43% C: 3.37%
conference global
SEED Therapeutics, BeyondSpring Subsidiary, Appoints Jackson Tai to Board of Directors
Published: 2023-06-20 (Crawled : 12:00) - globenewswire.com
BYSI | $1.805 2.56% 26K twitter stocktwits trandingview |
Health Technology
 | | O: -0.85% H: 9.4% C: 9.4%
BeyondSpring and Leading Cancer Center Present Poster Highlighting Plinabulin’s Ability to Reduce Infectious Neutropenic Fever for Multiple Myeloma Patients Undergoing AHCTData Presented at 2023 ASCO Annual Meeting
Published: 2023-06-07 (Crawled : 13:00) - biospace.com/
BYSI | $1.805 2.56% 26K twitter stocktwits trandingview |
Health Technology
 | | O: 3.2% H: 2.33% C: -3.1%
asco cancer meeting
BeyondSpring and Leading Cancer Center Present Poster Highlighting Plinabulin’s Ability to Reduce Infectious Neutropenic Fever for Multiple Myeloma Patients Undergoing AHCT
Published: 2023-06-07 (Crawled : 12:00) - globenewswire.com
BYSI | $1.805 2.56% 26K twitter stocktwits trandingview |
Health Technology
 | | O: 3.2% H: 2.33% C: -3.1%
cancer
BeyondSpring and Leading Cancer Center to Present Poster at 2023 ASCO Annual Meeting
Published: 2023-05-18 (Crawled : 12:00) - globenewswire.com
BYSI | $1.805 2.56% 26K twitter stocktwits trandingview |
Health Technology
 | | O: -1.3% H: 10.31% C: 6.19%
asco cancer meeting
BeyondSpring Provides Business Update and Reports Year End 2022 Financial Results
Published: 2023-04-18 (Crawled : 21:00) - globenewswire.com
BYSI | $1.805 2.56% 26K twitter stocktwits trandingview |
Health Technology
 | | O: 1.47% H: 0.0% C: -21.74%
business year update financial results
BeyondSpring Enrolls First Patient in Phase 2 Study with Plinabulin, Keytruda and Docetaxel in Patients with Metastatic Non-Small Cell Lung Cancer Who Progressed After Immunotherapy
Published: 2023-03-01 (Crawled : 13:20) - globenewswire.com
BYSI | $1.805 2.56% 26K twitter stocktwits trandingview |
Health Technology
 | | O: -0.53% H: 5.71% C: -1.06%
lung immunotherapy keytruda cancer study
BeyondSpring Presents Positive Data with Plinabulin for the Prevention of Docetaxel-Induced Neutropenia in Patients with Non-Small Cell Lung Cancer and Breast Cancer at Three Medical Conferences
Published: 2022-12-13 (Crawled : 20:00) - biospace.com/
BYSI | $1.805 2.56% 26K twitter stocktwits trandingview |
Health Technology
 | | O: 17.2% H: 35.14% C: 15.99%
lung plinabulin breast medical positive cancer
BeyondSpring Receives Nasdaq Notice Regarding Minimum Bid Price Requirements
Published: 2022-11-23 (Crawled : 22:00) - globenewswire.com
BYSI | $1.805 2.56% 26K twitter stocktwits trandingview |
Health Technology
 | Email alert Add to watchlist
nasdaq
Gainers vs Losers
55% 45%

Top 10 Gainers
WISA 4 | $5.33 204.57% 190M twitter stocktwits trandingview |
Electronic Technology
TPET | $0.5189 124.54% 38M twitter stocktwits trandingview |
n/a
SXTC | $1.78 52.14% 33M twitter stocktwits trandingview |
Health Technology
JAGX | $0.1771 49.07% 540M twitter stocktwits trandingview |
Health Technology
DYNT | $0.52 40.39% 20M twitter stocktwits trandingview |
Health Technology
BSGM | $1.53 39.09% 2.6M twitter stocktwits trandingview |
Health Technology
MCBC | $13.74 38.37% 1.6M twitter stocktwits trandingview |
Finance
FNCH | $2.98 32.74% 400K twitter stocktwits trandingview |
Professional, Scientific, and T...
PALI | $5.51 32.45% 28M twitter stocktwits trandingview |
Manufacturing
VERO | $0.804 31.8% 110K twitter stocktwits trandingview |
Health Technology
Your saved searches
Save your searches and get alerts when important news are released.